# Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

> **NCT04629703** · PHASE3 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 280 (actual)

## Conditions studied

- Covid19
- SARS (Severe Acute Respiratory Syndrome)
- SARS Pneumonia
- SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
- Pneumonia
- Pneumonia, Viral

## Interventions

- **DRUG:** Fostamatinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04629703
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-25
- **Primary completion:** 2022-09-05
- **Final completion:** 2022-09-05
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629703, "Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04629703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*